Last reviewed · How we verify
NCT07287839
Parcel-guided rTMS for Major Depressive Disorder
Phase 2 trial testing Accelerated rTMS in Treatment Resistant Depression (TRD) in 60 participants. Not yet recruiting.
1 June 2028
Quick facts
| Lead sponsor | Soterix Medical |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 15 December 2025 |
| Primary completion | 1 June 2028 |
| Estimated completion | 15 June 2028 |
Drugs / interventions tested
- Accelerated rTMS
- Parcel-guided Accelerated rTMS
Conditions studied
- Treatment Resistant Depression (TRD) — all drugs for Treatment Resistant Depression (TRD) →
Sponsor
Soterix Medical — full company profile →
Who can join
Adults 18 to 60, any sex, with Treatment Resistant Depression (TRD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study comparing standard repetitive transcranial magnetic stimulation (rTMS) for Depression to a novel targeting approach using brain surface parcellation to locate a specific brain target.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07287839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Treatment Resistant Depression (TRD)
Currently open trials in the same condition.
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06773949 — Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression · NA · recruiting
- NCT07264452 — Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst St · NA · recruiting
- NCT06682299 — Maintenance TMS in Treatment Resistant Depression · NA · recruiting
- NCT06668571 — Intravenous Ketamine for Treatment-Resistant Depression · Phase 2 · recruiting
Other Soterix Medical trials
Trials by the same sponsor.
- NCT07307768 — Ketamine Biomarker Validation · Phase 1 · not yet recruiting
- NCT07042217 — Transcranial Direct Current Stimulation for Depression · NA · recruiting
- NCT05598931 — Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI · completed
- NCT04956081 — Virtual Neuro-Navigation System for Personalized Community Based TMS · NA · completed
- NCT04781127 — Home-administered tDCS for Treatment of Depression · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07287839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Soterix Medical
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07287839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing